Pediapharm Competitors

Pediapharm (CVE:PDP) and Medicenna Therapeutics (TSE:MDNA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, analyst recommendations and valuation.

Earnings and Valuation

This table compares Pediapharm and Medicenna Therapeutics' gross revenue, earnings per share and valuation.

Medicenna Therapeutics has lower revenue, but higher earnings than Pediapharm. Medicenna Therapeutics is trading at a lower price-to-earnings ratio than Pediapharm, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations and price targets for Pediapharm and Medicenna Therapeutics, as reported by MarketBeat.com.

Profitability

This table compares Pediapharm and Medicenna Therapeutics' net margins, return on equity and return on assets.

Summary

Pediapharm beats Medicenna Therapeutics on 3 of the 3 factors compared between the two stocks.

Pediapharm (CVE:PDP) and Emblem (CVE:EMC) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations and valuation.

Earnings & Valuation

This table compares Pediapharm and Emblem's top-line revenue, earnings per share and valuation.

Pediapharm has higher revenue and earnings than Emblem. Emblem is trading at a lower price-to-earnings ratio than Pediapharm, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and target prices for Pediapharm and Emblem, as provided by MarketBeat.

Profitability

This table compares Pediapharm and Emblem's net margins, return on equity and return on assets.

Dividends

Pediapharm pays an annual dividend of C$0.14 per share and has a dividend yield of 46.7%. Emblem pays an annual dividend of $0.46 per share and has a dividend yield of 24.5%. Pediapharm pays out -191.8% of its earnings in the form of a dividend. Emblem pays out -242.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Summary

Pediapharm beats Emblem on 5 of the 7 factors compared between the two stocks.

Pediapharm (CVE:PDP) and Neptune Wellness Solutions (TSE:NEPT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations and valuation.

Valuation and Earnings

This table compares Pediapharm and Neptune Wellness Solutions' gross revenue, earnings per share and valuation.

Pediapharm has higher earnings, but lower revenue than Neptune Wellness Solutions. Pediapharm is trading at a lower price-to-earnings ratio than Neptune Wellness Solutions, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and target prices for Pediapharm and Neptune Wellness Solutions, as provided by MarketBeat.

Neptune Wellness Solutions has a consensus target price of C$4.63, suggesting a potential upside of 212.50%. Given Neptune Wellness Solutions' higher possible upside, analysts clearly believe Neptune Wellness Solutions is more favorable than Pediapharm.

Profitability

This table compares Pediapharm and Neptune Wellness Solutions' net margins, return on equity and return on assets.

Summary

Neptune Wellness Solutions beats Pediapharm on 4 of the 7 factors compared between the two stocks.

Pediapharm (CVE:PDP) and IMV (TSE:IMV) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations and valuation.

Valuation and Earnings

This table compares Pediapharm and IMV's gross revenue, earnings per share and valuation.

Pediapharm has higher revenue and earnings than IMV. IMV is trading at a lower price-to-earnings ratio than Pediapharm, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and target prices for Pediapharm and IMV, as provided by MarketBeat.

IMV has a consensus target price of C$5.08, suggesting a potential upside of 46.07%. Given IMV's higher possible upside, analysts clearly believe IMV is more favorable than Pediapharm.

Profitability

This table compares Pediapharm and IMV's net margins, return on equity and return on assets.

Summary

Pediapharm beats IMV on 4 of the 6 factors compared between the two stocks.

Pediapharm (CVE:PDP) and Fennec Pharmaceuticals (TSE:FRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations and valuation.

Profitability

This table compares Pediapharm and Fennec Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings and target prices for Pediapharm and Fennec Pharmaceuticals, as provided by MarketBeat.

Valuation and Earnings

This table compares Pediapharm and Fennec Pharmaceuticals' gross revenue, earnings per share and valuation.

Pediapharm has higher revenue and earnings than Fennec Pharmaceuticals. Fennec Pharmaceuticals is trading at a lower price-to-earnings ratio than Pediapharm, indicating that it is currently the more affordable of the two stocks.

Summary

Pediapharm beats Fennec Pharmaceuticals on 4 of the 6 factors compared between the two stocks.

Resverlogix (TSE:RVX) and Pediapharm (CVE:PDP) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends and risk.

Profitability

This table compares Resverlogix and Pediapharm's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Resverlogix and Pediapharm, as provided by MarketBeat.com.

Valuation & Earnings

This table compares Resverlogix and Pediapharm's revenue, earnings per share and valuation.

Resverlogix has higher earnings, but lower revenue than Pediapharm. Pediapharm is trading at a lower price-to-earnings ratio than Resverlogix, indicating that it is currently the more affordable of the two stocks.

Summary

Resverlogix beats Pediapharm on 2 of the 3 factors compared between the two stocks.